Trials / Completed
CompletedNCT04768608
PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer
Clinical Trial for the Safety and Efficacy of Non-viral PD1 Integrated Anti-PSMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Castrate-Resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- Male
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
PD1-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer
Detailed description
Clinical trial for the safety and efficacy of Non-viral programmed cell death protein-1(PD1) integrated anti-prostate-specific-membrane-antigen(PSMA) chimeric antigen receptor T(CART) cells in the treatment of Refractory Castrate-Resistant Prostate Cancer(CRPC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PD1-PSMA-CART cells | PD1-PSMA-CART cells will be given IV at split doses |
Timeline
- Start date
- 2021-12-23
- Primary completion
- 2022-06-30
- Completion
- 2023-05-30
- First posted
- 2021-02-24
- Last updated
- 2023-07-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04768608. Inclusion in this directory is not an endorsement.